AI Summary & Key Takeaways
AI InsightConclusion: In our study, no signifi cant difference was detected in reduction of central foveal thickness, improvement in visual acuity and number of injections between two agents.
📌 3 Key Takeaways
Özet
Purpose: To assess functional and anatomic effectiveness of intravitreal ranibizumab and afl ibercept injection given to patients with macular edema secondary to branch retinal vein occlusion. Method: We retrospectively reviewed fi les of 62 treatment-naive patients with macular edema due to branch retinal vein occlusion. The best-corrected visual acuity and optic coherence parameters were recorded on months 0, 1, 3, 6 and 12 in all patients. First 3 injections were performed in a monthly manner. Pro re nata (PRN) regimen was given during follow-up. Findings: Baseline visual acuity was 50.7±7.6 letters in ranibizumab group and 49.2±6.7 letters in afl ibercept group (p=0.403). No signifi cant difference was detected in visual acuity on month 12 between groups (p=0.313). Again, no signifi cant difference was detected in central foveal thickness on month 12 between groups (p=0.408). Mean number of intravitreal injection was 6.2±1.4 in ranibizumab group and 5.7±1.0 in afl ibercept group (p=0.174). At the end of month 12, complete recovery in subretinal detachment was detected in 16 patients (88.8%) receiving ranibizumab and 15 patients receiving afl ibercept (93.8%) (p=0.525). Conclusion: In our study, no signifi cant difference was detected in reduction of central foveal thickness, improvement in visual acuity and number of injections between two agents.